Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.52 |
| ▸ | HTR1D | P28221 | 9/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122381 | 0.80 | ALDH1A1 (0.53) | HTR2AHTR2CHTR6HTR1D | |
| SCHEMBL1122504 | 0.78 | HTR6 (0.49) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL1122358 | 0.76 | NOS3 (0.60) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL1122347 | 0.75 | HTR2C (0.64) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL1122382 | 0.73 | HTR6 (0.51) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL28814891 | 0.72 | HTR2A (0.51) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL27400363 | 0.72 | HTR2C (0.61) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL8589275 | 0.72 | MEN1 (0.52) | HTR2AHTR2CHTR6HTR1D | |
| SCHEMBL23956080 | 0.72 | HTR2C (0.69) | HTR2AHTR2CHTR6HTR1DNOS3 | |
| SCHEMBL7252922 | 0.72 | HTR2A (0.64) | HTR2AHTR2CHTR6HTR1DNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101247853-B | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-12 | — | — | CN | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| CN-101247853-A | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC (CA) | 2008-08-20 | — | — | CN | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR2A 156/4885HTR2C 434/4885HTR6 274/4885 |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR2A 156/4885HTR2C 434/4885HTR6 274/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | HTR2A 156/4885HTR2C 434/4885HTR6 274/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR2A 156/4885HTR2C 434/4885HTR6 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.